New aspects of the clinicopathology and genetic profile of metachronous multiple lung cancers

Annals of Surgery

Volumn 259, Issue 5, 2014, Pages 1018-1024

  Wu, Chen Tu ^a   Lin, Mong Wei ^a   Hsieh, Min Shu ^a   Kuo, Shuenn Wen ^b   Chang, Yih Leong ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

clonality; epidermal growth factor receptor; metachronous primary lung cancer; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLONAL VARIATION; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG CANCER; LUNG METASTASIS; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE PRIMARY LUNG CANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, SECOND PRIMARY; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAIWAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899491217     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000000385     Document Type: Article

References (39)

1. Ferguson MK, DeMeester TR, DesLauriers J, et al. Diagnosis andmanagement of synchronous lung cancers. J Thorac Cardiovasc Surg. 1985; 89: 378-385.
2. Chang YL, Wu CT, Lin SC, et al. Clonality and prognostic implications of P53 and EGFR somatic aberrations in multiple primary lung cancers. Clin Cancer Res. 2007; 13: 52-58.
3. Chang YL, Wu CT, Lee YC. Surg.ical treatment of synchronous multiple primary lung cancers: experience of 92 patients. J Thorac Cardiovasc Surg. 2007; 134: 630-637.
4. Van Bodegom PC, Wagenaar SS, Corrin B, et al. Second primary lung cancer: importance of long term follow up. Thorax. 1989; 44: 778-793.
5. Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer. 1932; 16: 1358-1403.
6. Nelson MA, Wymer J, Clements N, Jr. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett. 1996; 103: 115-121.
7. HiroshimaK, Toyozaki T, Kohno H, et al. Synchronous andmetachronous lung carcinomas: molecular evidence for multicentricity. Pathol Int. 1998; 48: 869-876.
8. Martini N, Melamed MR.Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975; 70: 606-612.
9. Detterbeck FC, Jones DR, Funkhouser WK, Jr. Satellite nodules and multiple primary cancers. In: Detterbeck FC, Rivera MP, Socinski MA, et al. eds. Diagnosis and Treatment of Lung Cancer: An Evidence-Based Guide for the Practicing Clinician. Philadelphia, PA: WB Saunders; 2001; 437-449.
10. Shen KR, Meyers BF, Larner JM, et al. Special treatment issues in lung cancer. ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007; 132: 290s-305s.
11. Girard N, Deshpande C, Lau C, et al. Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg. Pathol. 2009; 33: 1752-1764.
12. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochem Biophys Acta. 1998; 1378: F21-F59.
13. Mitsudomi T, Steinberg S, NauMM, et al. P53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992; 7: 171-180.
14. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev med. 2003; 54: 73-87.
15. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004; 59: 21-26.
16. Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004; 10: 4227-4232.
17. Hirsch FR, Scagliotti GV, Langer CJ, et al. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspective for targeted therapies. Lung Cancer. 2003; 41: S29-S42.
18. Mendelsohn J, Baselga J. TheEGFreceptor family as targets for cancer therapy. Oncogene. 2000; 19: 6550-6565.
19. Shigematsu H, Lin L, Takahashi Y, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005; 97: 339-346.
20. Johnson BE, Janne PA. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 2005; 65: 7525-7529.
21. Mitsudomi T, YatabeY.Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007; 98: 1817-1824.
22. Shimizu S, Yatabe Y, Koshikawa T, et al. High frequency of clonality related tumors in cases of multiple synchronous lung cancers as revealed by molecular diagnosis. Clin Cancer Res. 2000; 6: 3994-3999.
23. Mitsudomi T, Yatabe Y, Koshikawa T, et al. Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. J Thorac Cardiovasc Surg. 1997; 114: 354-360.
24. Matsuzoa D, Hideshima T, Ohshima K, et al. Discrimination of double primary lung cancer from intrapulmonary metastasis by P53 genemutation. Br JCancer. 1999; 79: 1549-1552.
25. Van Rens MT, Eijken EJ, Elbers JR, et al. P53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer. 2002; 94: 188-196.
26. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res. 2005; 65: 7568-7572.
27. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as amechanism associated with resistance to EGFR-targeted agents: a systemic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008; 9: 962-972.
28. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of P53 mutant cells is associated with brain tumour progression. Nature. 1992; 355: 846-847.
29. Struve-Christensen E. Diagnosis and treatment of bilateral primary bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1971; 61: 501-513.
30. Shields TW, Drake CT, Sherrick JC. Bilateral primary bronchogenic carcinoma. J Thorac Cardiovasc Surg. 1964; 48: 401-413.
31. Chaudhuri MR. Independent bilateral primary bronchial carcinomas. Thorax. 1971; 26: 476-480.
32. Shields TW, Humphrey EW, Higgins GA, Jr, et al. Long-term survivors after resection of lung carcinoma. J Thorac Cardiovasc Surg. 1978; 76: 439-445.
33. Antakli T, Schaefer RF, Rutherford JE, et al. Second primary lung cancer. Ann Thorac Surg. 1995; 59: 863-867.
34. Slaughter DP, Southwick HW, SmejkaiW. "Field cancerization" in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer. 1953; 6: 693-698.
35. Hida T, Ariyoshi T, Sugiura T, et al. Synchronous lung cancer presenting with small cell carcinoma and adenocarcinoma. Chest. 1993; 104: 1602-1604.
36. RichardsonGE, Tucker MA, VenzonDJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med. 1993; 119: 383-390.
37. Tanvetyanon T, Robinson L, Sommers KE, et al. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol. 2010; 5: 1018-1024.
38. Rosengart T, Martini N, Ghosn P, et al. Multiple primary lung carcinomas prognosis and treatment. Ann Thorac Surg. 1991; 52: 773-779.
39. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg. 1997; 113: 37-49.